Janux Therapeutics, Inc. (JANX)
About Janux Therapeutics, Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$113.6M
- Total assets
- $1.0B
- Market cap
- $814.8M
- Operating margin
- -1576.7%
- Net margin
- -1136.2%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $10.0M
- Operating expenses
- $167.7M
- Operating income
- -$157.7M
- Income tax
- $0
- Net income
- -$113.6M
- EPS (basic)
- $-1.83
- EPS (diluted)
- $-1.83
Balance sheet
- Total assets
- $1.0B
- Current assets
- $975.9M
- Total liabilities
- $44.7M
- Current liabilities
- $25.0M
- Shareholders’ equity
- $956.8M
Cash flow
- Operating cash flow
- -$82.2M
- Investing cash flow
- -$301.0M
- Financing cash flow
- $4.9M
- Net cash flow
- -$378.3M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $814.8M
- EPS (diluted)
- $-1.83
- Shares outstanding
- 53.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 11, 2021
Janux Therapeutics, Inc. (JANX) Stock Price
- Reported a net loss of $113.6M.
- Revenue grew 175% from FY2021 to FY2025.
- Trading 56% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Janux Therapeutics, Inc..
Write a review
News about Janux Therapeutics, Inc.
News & sentiment via Polygon.io
Janux Therapeutics, Inc.: frequently asked questions
Is Janux Therapeutics, Inc. an American company?
Janux Therapeutics, Inc. is a US-based company headquartered in San Diego, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Janux Therapeutics, Inc. headquartered?
Janux Therapeutics, Inc. is headquartered in San Diego, California, United States.
Is Janux Therapeutics, Inc. publicly traded?
Yes — Janux Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol JANX on the NASDAQ.
What does Janux Therapeutics, Inc. do?
Janux Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
